metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | |
mNSCLC - L1 - PDL1 negative | |
nivolumab based treatment | |
nivolumab plus SoC | CheckMate 227 ... |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -